Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.42 |
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 2/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16562304 | 0.84 | MEN1 (0.49) | TMEM97SIGMAR1MEN1KMT2AACKR3 | |
| SCHEMBL13918962 | 0.77 | BCHE (0.54) | BCHEBACE1MEN1KMT2AGSR | |
| SCHEMBL13154916 | 0.75 | BCHE (0.49) | BCHEBACE1SIGMAR1MEN1KMT2A | |
| SCHEMBL16559754 | 0.72 | SIGMAR1 (0.40) | BCHETMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL13918966 | 0.72 | ALDH1A1 (0.47) | TMEM97SIGMAR1MEN1KMT2AHIF1A | |
| SCHEMBL13166771 | 0.69 | BCHE (0.51) | BCHEBACE1MEN1KMT2ASCN8A | |
| SCHEMBL13336035 | 0.68 | KDM4E (0.43) | BCHETMEM97SIGMAR1HIF1AKDM4E | |
| SCHEMBL31638054 | 0.67 | SIGMAR1 (0.60) | BCHESIGMAR1MEN1KMT2APDCD1 | |
| SCHEMBL17664610 | 0.67 | BCHE (0.51) | BCHEBACE1SIGMAR1SCN8A | |
| SCHEMBL13166761 | 0.67 | BCHE (0.49) | BCHEBACE1MEN1KMT2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | BCHE 1377/4885BACE1 3251/4885TMEM97 2372/4885 |
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | BCHE 1377/4885BACE1 3251/4885TMEM97 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.